Tumors were completely wiped out in three of nine people with advanced
melanoma who were given the drug for two weeks.
"Their tumors, which you could see outside the body before treatment,
completely disappeared," James Goydos, MD, tells WebMD. Goydos is a
surgical oncologist at the University of Medicine and Dentistry of New
Jersey-Robert Wood Johnson Medical School in New Brunswick.
In two more patients, imaging scans showed that tumors had shrunk. Three
more patients remained stable. One patient got worse, with signs of tumor
The researchers tracked the patients' progress before and after the
treatment with biopsies and PET scans, a form of nuclear-medicine imaging
typically used to detect cancer.
The results were presented at the annual meeting of the American Association
for Cancer Research.
Riluzole Lowers Glutamate Levels
Each year, more than 53,600 people in the U.S. are diagnosed with melanoma,
according to the National Cancer Institute (NCI). In the past 30 years, the
number of Americans who develop melanoma annually has more than doubled.
In about 70% of cases, people with melanoma develop lesions in body areas
that are exposed to the sun. The cancer can then spread to other parts of the
body -- typically the lymph nodes first and then other organs.
The new study involved people whose disease had spread, or metastasized, to
the lymph nodes.
The work builds on the research team's earlier discovery that melanoma cells
release a lot of a substance called glutamate.
Too much glutamate can overstimulate brain cells to the point that they burn
out -- a possible explanation of what happens in ALS, says Suzie Chen, PhD, a
professor of chemical biology at Rutgers University.
Riluzole, also sold as Rilutek, fights ALS by lowering glutamate levels.
"So my collaborators said, let's test it against melanoma. And much to our
surprise, the drug slowed the growth rate of melanoma cells [in the test
tube]," Chen says.
In animal studies, riluzole again suppressed tumor cell growth and
progression, she says. The researchers were then able to secure an NCI grant to
perform a new type of first-in-human study; it's designed to validate if a drug
will perform as expected in humans -- "to see if you are hitting your
targets," Goydos says.
"This is the very first time we have treated melanoma patients with drugs that target [glutamate] and a significant number
of patients responded," he says. The only significant side effect was dizziness, according to